Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on May 29, 2018, to disclose the filing of a prospectus supplement related to the resale of up to 252,497 shares of its common stock by certain stockholders. This filing does not involve new equity issuance by the company itself, but rather facilitates the sale of existing shares by identified selling stockholders. This event is primarily administrative and legal in nature, confirming the legality of these shares for resale through an opinion from their counsel, O’Melveny & Myers LLP. Investors should note that this is not an offering of new shares, but rather a mechanism for existing shareholders to sell their holdings. The company itself is not raising capital through this filing.
Key Highlights
- 1Edwards Lifesciences (EW) filed an 8-K on May 29, 2018, related to a prospectus supplement.
- 2The prospectus supplement allows for the resale of up to 252,497 shares of common stock by named stockholders.
- 3The filing is an administrative action to facilitate the sale of existing shares, not a new equity offering by the company.
- 4An opinion from legal counsel, O’Melveny & Myers LLP, regarding the legality of the common stock being registered was filed.
- 5The company is not raising capital through this specific 8-K filing.
- 6The filing relates to a shelf registration statement previously filed on Form S-3.
Frequently Asked Questions
No, this filing pertains to the resale of existing shares by stockholders named in the prospectus supplement. The company is not issuing new shares or raising capital through this 8-K.
The prospectus supplement provides the necessary legal documentation to allow certain stockholders to offer and sell up to 252,497 shares of Edwards Lifesciences' common stock from time to time.
The opinion from their legal counsel confirms the legality of the common stock being registered for resale by the stockholders, fulfilling regulatory requirements for such filings.
This filing is primarily administrative and legal. It does not directly impact the company's ongoing operations or immediate financial health, as it concerns the resale of shares by existing shareholders rather than new company financing.